ABSTRACT Patients with clear cell renal carcinoma (ccRCC) often relapse after nephrectomy, even for those with localized or locally advanced diseases. However, ideal prognostic biomarkers specifically for localized, locally advanced, and metastatic ccRCC are inadequate. In this paper, we systematically identified potential biomarkers for disease-free prognosis of patients with ccRCC. The expression and clinical data of The Cancer Genome Atlas (TCGA, n = 603) and international cancer genomics consortium (ICGC, n = 392) were leveraged to identify long non-coding RNA (lncRNA)-based prognostic markers. The expression data of GSE53757 (n = 144) and GSE66270 (n = 28) from Gene Expression Omnibus (GEO) were used to screen for ccRCC-related differentially expressed (DE) genes. 893 DE lncRNAs in common of the three datasets were screened out [Benjamini-Hochberg (BH) adjusted P < 0.05]. Univariate and multivariate Cox analysis revealed that the 2-lncRNA signature (LINC00176 and CTD-2145C24.5) could be an independent prognostic marker for DFS of patients with localized ccRCC (log-rank P = 0.006). Another 5-lncRNA signature (DSCR9, RP11-271C24.2, RP11-424M24.5, CTD-2171N6.1, and CTC-499B15.8) have great potential in the disease-free prognosis not only of patients with locally advanced (log-rank P < 0.001) disease but also for patients with metastatic disease (log-rank P < 0.001). Functional analysis shown that the 2-lncRNA signature was associated with protein deacetylation and RNA splicing (BH-adjusted P < 0.05), while 5-lncRNA signature was associated with deoxyribonuclease activity, RNA−dependent ATPase activity, and helicase activity (BH-adjusted P < 0.05). We identified two lncRNA signatures for DFS prognosis of patients with ccRCC, which may be valuable clinical tools at molecular-level. Biomarker, biomedical computing, bioinformatics. 
I. INTRODUCTION
Based on GLOBOCAN cancer statistics in 2018, approximately 400,000 new cases of kidney cancer were diagnosed worldwide (1) . Patients with localized (i.e., clinical stage I/II) kidney cancer shown 5-year survival > 90% (2). However, 5-year survival drops to 12% for patients with distant metastasis (2) . About 90% of kidney cancer is renal cell carcinoma (RCC). The most common histologic subtype of RCC is clear cell RCC (ccRCC) (3) . Patients with localized RCC usually be treated through surgical removal
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of part or all of the kidney (4). However, over 30% of patients with intermediate-or high-risk RCC were predicted to postsurgical relapse within 5 years (5) . Cancer that has spread beyond the kidney contributed to the poor outcomes (4) . Patients with locally-advanced RCC (the tumor has grown out of the kidney into surrounding tissue or regional lymph nodes, but without distant metastasis) or metastatic RCC (the tumor has spread to distant lymph nodes or other organs) may be treated with surgery, sometimes combined with antiangiogenic therapy and immunotherapy (6) . Current systems for the prognosis of ccRCC depend on the evaluation of clinical factors, without prognostic or predictive marker identified (7) . Moreover, there are significant differences in disease-free survival (DFS) from localized, locally-advanced and metastatic ccRCCs. Therefore, identification of molecular-level disease-free prognostic biomarkers is warranted for clinical management of localized, locally-advanced and metastatic ccRCC.
Long non-coding RNA is a kind of RNA without the ability to encode proteins. Recent studies have revealed lncRNAs play a critical role in tumor progression and have the potential to be therapeutic targets (8) . For example, lncARSR was linked to sunitinib resistance of advanced RCC (9) . It was reported that lncARSR can competitively bind miR-34/miR-449 to overexpress AXL and c-MET (9) . However, the potential utility of lncRNAs in clinical applications such as disease-free prognosis has not been fully investigated. In this study, we systematically evaluated the prognostic value of identified 7678 lncRNAs in DFS of patients with localized, locally-advanced or metastatic ccRCC.
II. MATERIALS AND METHODS

A. DATA ACQUISITION
Microarray datasets (GSE53757 (10) and GSE66270 (11)) from the Affymetrix Human Genome U133 Plus 2.0 Array platform were obtained from the GEO database. The raw CEL files and platform annotation file were downloaded. A total of 72 ccRCC samples and 72 normal controls were downloaded from GSE53757. 14 ccRCC samples and 14 normal controls were downloaded from GSE66270. The RNA-Seq data (HT-Seq read counts) and the corresponding clinical information of TCGA KIRC (n = 603) were downloaded from the Genomic Data Commons (GDC) data portal (https://portal.gdc.cancer.gov/repository). To obtain the expression profiles of lncRNAs, GENCODE (v22) gene annotation file (GTF) was used. The genes with identifier 'lincRNA' in the annotation file were considered as lncRNA genes. The international cancer genomics consortium (ICGC) dataset with 392 ccRCC patients was also downloaded for validation of survival.
B. DIFFERENTIAL EXPRESSION ANALYSIS
The raw CEL files were preprocessed using affy package (12) in R software (version 3.5.1). In this step, the expression matrix was background corrected and quantile normalized. Limma package (13) was used to perform differential expression analysis for microarray. DESeq2 package (14) was used to perform differential expression analysis for HT-Seq read counts data. LncRNAs with Benjamini-Hochberg adjusted P values < 0.05 and with deregulation status in common for TCGA datasets and GEO datasets were considered as differentially expressed (DE) lncRNAs.
C. UNIVARIATE AND MULTIVARIATE Cox REGRESSION
The univariate and multivariate Cox proportional hazard regression was performed to evaluate the DFS of patients with ccRCC using survival package (15) in R software. DE lincRNAs with a log-rank P value < 0.01 in the univaraite analysis was collected for multivariate analysis. Multivariate analysis of lncRNAs was employed to determine the lncRNA signature. The Prognostic index (Pindex) was subsequently calculated based on the lncRNA signature using the following formula:
where n is the number of lncRNAs in the signature, Exp i is the expression level of lncRNA i, and β i is the estimated regression coefficient of lncRNA i in the multivariate Cox model. To assess whether clinical factors were influential for the multivariate model, candidate variables including grade, The patients were divided into high-or low-group using the median value of the prognostic index (Pindex) as a cut-off, which was calculated based on the expression of 2-lncRNA signature or 5-lncRNA signature.
primary tumor (pT), regional lymph nodes (pN), distant metastasis (pM), age and gender were added into the multivariate model. Any clinical variable with log-rank P value < 0.05 in the multivariate model was considered significant and was adjusted.
D. FUNCTION ANALYSIS OF lncRNAs
To predict the biological function of lncRNAs, we performed Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis based on the protein-coding genes that co-expressed with our interested lncRNAs. Prior to this, DE coding genes were screened for co-expression analysis. The same methods as above were utilized to identify DE coding genes. LncRNA-gene pairs with Pearson correlation coefficients |r| ≥ 0.4 and P < 0.01 was screened for enrichment analysis. GO terms and KEGG pathways with BH-adjusted P values < 0.05 were considered statistically significant.
III. RESULTS
A. IDENTIFICATION OF DIFFERENTIALLY EXPRESSED lncRNAs IN ccRCC
As our goal is to identify lncRNA-based prognostic markers, the lncRNA expression profiles from TCGA dataset and GEO dataset were firstly extracted using GENCODE v22 annotation (GTF file). The expression matrices of a total of 7678 lncRNA were extracted. To identify lncRNAs that played a role in ccRCC, we performed differential expression analysis between ccRCC tumors and control samples based on TCGA dataset and GEO dataset separately. 789 genes were upregulated and 645 genes were downregulated in the TCGA dataset. 741 genes were upregulated and 451 genes were downregulated in the GSE53757 dataset. 662 genes were upregulated and 560 genes were downregulated in the GSE66270 dataset. A total of 893 differentially expressed (DE, BH-adjusted P < 0.05) lncRNAs (515 upregulated and 378 downregulated) were identified in the three datasets ( Fig. 1a) . The expression of 893 DE lncRNAs in TCGA dataset was visualized (Fig. 1b) . We next performed DFS analysis for ccRCC patients based on their pathological stages. As shown in Fig. 1c , the DFS of patients with high stage (stage III/IV) ccRCC was significantly poorer than those with the low stage (stage I/II) ccRCC (Fig. 1c) . Moreover, the difference in patients' survival between these two groups was very apparent (log-rank P < 2e-16, Fig. 1c) . Thus, the DFS-related biomarker identification was separately performed for the high-and low-stage ccRCC patients.
B. 2-lncRNA SIGNATURE COULD BE A PROGNOSTIC BIOMARKER FOR DFS OF STAGE I/II ccRCC PATIENTS
Firstly, we performed univariate Cox proportional hazard regression for patients with stage I/II ccRCC based on TCGA dataset (training, n = 283) and ICGC dataset (validation, n = 260). Totally 80 lncRNAs with log-rank P value < 0.01 were considered statistically significant and were subjected to the multivariate model. We found that 2-lncRNA signature (LINC00176 and CTD-2145C24.5) was significantly associated with DFS of patients with stage I/II ccRCC (logrank P = 0.006). Based on this signature, the Pindex was calculated using our formula (see Materials and Methods, Fig. 2a , Table 1 ). The median value of Pindex was used as a cut-off to divide patients into high-and low-Pindex groups.
To investigate whether the clinical factors were associated with our Pindex, we further performed multivariate analysis using the Pindex (median value was used as the cut-off value to divide patients into high-and low-Pindex groups) and traditional clinical factors as candidate variables, such as VOLUME 7, 2019 grade, pT, age, and gender. The results shown that our Pindex was an independent prognostic factor for DFS of patients with stage I/II ccRCC in both training dataset (log-rank P = 0.004, Table 1 ) and validation dataset (log-rank P = 0.021, Fig. 2b , Table 1 ).
C. 5-lncRNA SIGNATURE COULD BE A PROGNOSTIC BIOMARKER FOR DFS OF STAGE III/IV ccRCC PATIENTS
We next identified DFS-related biomarker for patients with stage III/IV ccRCC. Similarly, the TCGA dataset with 151 patients and the ICGC dataset with 132 patients for training and validation, respectively. As a result, univariate analysis showed that 10 lncRNAs were significantly associated with DFS of patients with stage III/IV ccRCC (log-rank P value < 0.01). Multivariate analysis for the 10 lncRNAs revealed a 5-lncRNA signature (DSCR9, RP11-271C24.2, RP11-424M24.5, CTD-2171N6.1 and CTC-499B15.8). The Pindex of the 5-lncRNA signature was subsequently calculated. However, this 5-lncRNA model was shown to be affected by pM (log-rank P = 7.03e-06, Table 2 ) ccRCC. Thus, we adjusted this model using pM as a variable. The DFS of patients with high-Pindex (median value as the cut-off) was significantly poorer than that of patients with low-Pindex (log-rank P < 0.001, Fig. 2c , Table 2 ), independent of pM variable. This was further validated using validation dataset (log-rank P = 0.009, Fig. 2d , Table 2 ). Therefore, our identified 5-lncRNA signature could be a biomarker coupled with pM for DFS prognosis of patients with stage III/IV ccRCC. Taken above together, both lncRNA signatures could be biomarkers for the DFS prognosis of patients with ccRCC (Fig. 3) .
D. FUNCTIONAL ANALYSIS FOR THE TWO lncRNA SIGNATURES
To investigate the potential functions and pathways involved in the lncRNA signatures, we performed GO and KEGG enrichment analysis for 2-lncRNA signature and 5-lncRNA signature, respectively. Firstly, 431 DE protein-coding genes and 582 DE protein-coding genes that co-expressed with the 2-lncRNA signature and 5-lncRNA signature, respectively, were identified (Pearson |r| ≥ 0.4 and P < 0.01). The DE protein-coding genes were identified between ccRCC patients and control samples in the TCGA dataset and the GEO datasets. Then, functional enrichment analyses were conducted based on DE protein-coding genes. Results shown that the 2-lncRNA signature was only significantly involved in biological processes such as histone deacetylation, protein deacetylation and RNA splicing (Fig. 4a) . The 5-lncRNA was mainly involved in DNA replication, cell cycle checkpoint, DNA damage checkpoint and RNA splicing biological processes (BH-adjusted P < 0.05, Fig. 4b ). The 5-lncRNA signature was also associated with the molecular functions, such as deoxyribonuclease activity, RNA−dependent ATPase activity and helicase activity (Fig. 4c) . KEGG enrichment revealed that the 5-lncRNA signature was associated with homologous recombination, oocyte meiosis and herpes simplex virus 1 infection (BH-adjusted P <0.05, Fig. 4d ). For 2-lncRNA signature, although no KEGG pathway with BH-adjusted P < 0.05 was shown, signaling pathways such as glycerophospholipid metabolism (hypergeometric test, P = 4.06e-05, BH-adjusted P = 0.079), Ras (P = 0.001, BH-adjusted P = 0.114) and Oxytocin (P = 0.002, BH-adjusted P = 0.133) has the greatest potential to associate with 2-lncRNA signature. Therefore, enrichment analysis based on the DE protein-coding genes that co-expressed with the lncRNA signatures further predicted their potential functions and signaling pathways.
IV. DISCUSSION
As the significant differences in DFS between localized, locally-advanced and metastatic ccRCCs, the purpose of this study was to systematically assess the potential value of lncRNAs for specific disease-free prognosis of patients with ccRCC. Firstly, we identified 7678 lncRNAs based on GENCODE database. Secondly, we performed differential expression analysis to further screening for ccRCC-related lncRNAs. The lncRNA-based prognostic biomarker identification was based on the DE lncRNAs. This process was separately performed for patients of stage I/II and stage III/IV, as the relapse rate of the patients in the two groups with highly discrepancy. Our identified 2-lncRNA signature (LINC00176 and CTD-2145C24.5) could be an independent factor for DFS prognosis of patients with localized ccRCCs. Another 5-lncRNA signature (DSCR9, RP11-271C24.2, RP11-424M24.5, CTD-2171N6.1 and CTC-499B15.8) for DFS prognosis of patients with stage III/IV disease was also identified. The Cox regression model fitted by the 5-lncRNA signature has prognostic value for both locally-advanced ccRCC and metastatic ccRCC. Taken together, the two lncRNA signatures may be a valuable clinical tool for DFS prognosis of patients with ccRCC. LncRNAs with prognostic value often play a critical role in tumor progression (16) . To predict the potential function and signaling pathways involved by our lncRNA signatures, we employed GO and KEGG pathway enrichment analysis based on the DE protein-coding genes that co-expressed with the lncRNA signatures. Our analysis shown that the 2-lncRNA signature was associated with protein deacetylation and RNA splicing, while 5-lncRNA signature was associated with deoxyribonuclease activity, RNA−dependent ATPase activity and helicase activity. To date, The 7 lncRNAs have not reported in ccRCC. Among them, LINC00176, DSCR9 and CTD-2171N6.1 were reported in studies of other diseases. LINC00176 was reported to be regulated by Myc/Max and AP-4 transcription regulators in liver cancer cells (17) . Upregulation of LINC00176 promoted cell proliferation and cell survival by suppressing mir-9/mir-185 expression (17) . DSCR9 was firstly identified in the Down Syndrome Critical Region (DSCR) of chromosome 21 (18) , which may be associated with the developments of the nervous system (19) , human iris (eye) color (20) and epigenetic regulation of malignant prostate cells (21) . CTD-2171N6.1 was reported in papillary thyroid cancer (PTC) (22) . The expression of CTD-2171N6.1 alone was not associated with DFS of patients with PTC, while a 3-lncRNA signature (CTD-2171N6.1, AC079630.2 and CRNDE) was significantly related to DFS of patients with PTC (22) . Therefore, the two lncRNA-based signatures are novel prognostic biomarkers for patients with ccRCCs.
In summary, we identified two novel lncRNA-based signature for DFS prognosis of patients with ccRCC, which may be a valuable clinical tool. Especially, the 2-lncRNA signature (LINC00176 and CTD-2145C24.5) could be an independent prognostic marker for DFS of patients with localized ccRCCs. Another 5-lncRNA signature (DSCR9, RP11-271C24.2, RP11-424M24.5, CTD-2171N6.1 and CTC-499B15.8) could be an independent prognostic marker for DFS prognosis of patients with stage III/IV disease. Functional analysis showed that they may play pivotal roles in the relapse of patients with ccRCC. The molecular roles of our identified two lncRNA signatures remain unclear and warrant further characterization.
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